Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-12 04:50 | 2025-08-21 | GNLX | GENELUX Corp | Zindrick Thomas | Officer | SELL | $3.86 | 17,182 | $66,371 | 538,431 |
| 2025-12-12 04:50 | 2025-08-21 | GNLX | GENELUX Corp | Yu Yong | Officer | SELL | $3.82 | 4,192 | $16,032 | 145,844 |
| 2025-12-12 04:49 | 2025-08-21 | GNLX | GENELUX Corp | Cappello Joseph | Officer | SELL | $3.88 | 3,706 | $14,361 | 156,060 |
| 2025-12-12 01:35 | 2025-12-09 | IRD | Opus Genetics, Inc. | Foundation Fighting Blindness Retinal Degeneration Fund | Director | SELL | $2.15 | 4,000,000 | $8,600,000 | 5,492,171 |
| 2025-12-12 00:21 | 2025-12-09 | BIOA | BioAge Labs, Inc. | RUBIN PAUL D | Officer | OPT+S | $12.00 | 18,000 | $216,000 | 0 |
| 2025-12-11 02:49 | 2025-12-10 | IMMX | Immix Biopharma, Inc. | Rachman Ilya M | Director, Officer | BUY | $6.67 | 746 | $4,976 | 1,141,683 |
| 2025-12-11 02:47 | 2025-12-10 | IMMX | Immix Biopharma, Inc. | Morris Gabriel S | Director, Officer | BUY | $6.58 | 770 | $5,067 | 291,429 |
| 2025-12-11 00:30 | 2025-12-08 | NUVL | Nuvalent, Inc. | Balcom Alexandra | Officer | SELL | $110.32 | 7,084 | $781,537 | 54,650 |
| 2025-12-11 02:48 | 2025-12-08 | TENX | TENAX THERAPEUTICS, INC. | Rich Stuart | Director, Officer | BUY | $10.16 | 5,000 | $50,793 | 5,266 |
| 2025-12-11 00:52 | 2025-12-08 | SNSE | Sensei Biotherapeutics, Inc. | Peyer James | 10% owner | OPT+S | $8.25 | 6,612 | $54,575 | 155,142 |
| 2025-12-11 00:29 | 2025-12-08 | MLTX | MoonLake Immunotherapeutics | Santos da Silva Jorge | Director, Officer | SELL | $14.87 | 200,000 | $2,974,700 | 2,878,577 |
| 2025-12-11 00:29 | 2025-12-08 | MLTX | MoonLake Immunotherapeutics | Reich Kristian | Officer | SELL | $14.85 | 202,908 | $3,012,453 | 0 |
| 2025-12-11 00:05 | 2025-12-08 | VERA | Vera Therapeutics, Inc. | Turner William D. | Officer | OPT+S | $45.31 | 10,000 | $453,053 | 22,500 |
| 2025-12-11 00:56 | 2025-12-09 | SNSE | Sensei Biotherapeutics, Inc. | Cambrian BioPharma Inc | 10% owner | OPT+S | $8.25 | 6,612 | $54,575 | 155,142 |
| 2025-12-10 15:53 | 2025-12-08 | BBIO | BridgeBio Pharma, Inc. | Apuli Maricel | Officer | SELL | $74.26 | 2,000 | $148,520 | 130,297 |
| 2025-12-11 01:06 | 2025-12-08 | KNSA | Kiniksa Pharmaceuticals International, plc | Ragosa Mark | Officer | OPT+S | $41.49 | 42,841 | $1,777,473 | 31,086 |
| 2025-12-11 04:51 | 2025-12-08 | XCUR | EXICURE, INC. | SANGSANGIN INVESTMENT & SECURITIES CO., LTD. | 10% owner | SELL | $8.71 | 433,332 | $3,774,322 | 0 |
| 2025-12-11 01:13 | 2025-12-08 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | Officer | SELL | $21.02 | 6,663 | $140,073 | 263,311 |
| 2025-12-11 01:45 | 2025-11-26 | MRUS | Merus N.V. | Shuman Harry | Officer | OPT+S | $96.10 | 1,700 | $163,370 | 11,002 |
| 2025-12-11 05:45 | 2025-12-08 | WVE | Wave Life Sciences Ltd. | Wagner Heidi L | Director | OPT+S | $13.50 | 14,000 | $189,000 | 44,930 |
| 2025-12-11 05:45 | 2025-12-08 | WVE | Wave Life Sciences Ltd. | Tan Aik Na | Director | OPT+S | $13.58 | 134,218 | $1,823,164 | 25,400 |
| 2025-12-11 05:45 | 2025-12-08 | WVE | Wave Life Sciences Ltd. | Francis Chris | Officer | OPT+S | $14.57 | 441,031 | $6,427,101 | 25,000 |
| 2025-12-11 05:45 | 2025-12-08 | WVE | Wave Life Sciences Ltd. | Moran Kyle | Officer | OPT+S | $15.78 | 260,036 | $4,103,966 | 90,365 |
| 2025-12-11 00:24 | 2025-12-08 | STOK | Stoke Therapeutics, Inc. | Allan Jonathan | Officer | SELL | $32.28 | 3,978 | $128,411 | 11,831 |
| 2025-12-11 05:45 | 2025-12-08 | WVE | Wave Life Sciences Ltd. | Verdine Gregory L. | Director | SELL | $13.47 | 20,000 | $269,460 | 275,217 |
| 2025-12-11 05:45 | 2025-12-08 | WVE | Wave Life Sciences Ltd. | Rawcliffe Adrian | Director | OPT+S | $15.00 | 42,000 | $630,000 | 12,700 |
| 2025-12-11 00:23 | 2025-12-08 | STOK | Stoke Therapeutics, Inc. | Kaye Edward M. MD | Director | SELL | $32.27 | 13,430 | $433,385 | 49,124 |
| 2025-12-11 00:05 | 2025-12-09 | KURA | Kura Oncology, Inc. | Hasnain Faheem | Director | OPT+S | $10.98 | 10,000 | $109,764 | 23,983 |
| 2025-12-11 00:42 | 2025-12-08 | FULC | Fulcrum Therapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. | 10% owner | SELL | $13.98 | 4,175,139 | $58,377,211 | 6,053,960 |
| 2025-12-11 05:38 | 2025-12-09 | CRMD | CorMedix Inc. | Lefkowitz Steven W | Director | SELL | $11.88 | 40,000 | $475,200 | 80,498 |
| 2025-12-11 00:32 | 2025-12-08 | COLL | COLLEGIUM PHARMACEUTICAL, INC | Dreyer Scott | Officer | OPT+S | $48.17 | 17,600 | $847,855 | 103,613 |
| 2025-12-11 05:45 | 2025-12-08 | WVE | Wave Life Sciences Ltd. | HENRY CHRISTIAN O | Director | OPT+S | $14.65 | 93,445 | $1,369,324 | 12,700 |
| 2025-12-11 05:45 | 2025-12-08 | WVE | Wave Life Sciences Ltd. | CORRIGAN MARK | Director | SELL | $13.48 | 16,115 | $217,298 | 28,815 |
| 2025-12-10 16:15 | 2025-12-08 | GALT | GALECTIN THERAPEUTICS INC | Shlevin Harold H. | Director | OPT+S | $6.00 | 175,790 | $1,055,303 | 11,206 |
| 2025-12-11 00:54 | 2025-12-09 | UTHR | UNITED THERAPEUTICS Corp | Mesa Nilda | Director | SELL | $481.63 | 187 | $90,065 | 5,286 |
| 2025-12-11 00:53 | 2025-12-09 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $479.17 | 8,000 | $3,833,374 | 130 |
| 2025-12-11 00:15 | 2025-12-08 | PAHC | PHIBRO ANIMAL HEALTH CORP | BENDHEIM JACK | Director, Officer, 10% owner | SELL | $40.10 | 4,808 | $192,781 | 44,952 |
| 2025-12-10 00:57 | 2025-12-05 | SION | Sionna Therapeutics, Inc. | Fitzpatrick Jennifer | Officer | OPT+S | $40.52 | 10,250 | $415,330 | 0 |
| 2025-12-10 00:51 | 2025-12-05 | MAIA | MAIA Biotechnology, Inc. | Smith Stan | Director | BUY | $1.20 | 13,740 | $16,441 | 4,580 |
| 2025-12-10 03:07 | 2025-12-09 | CNTA | Centessa Pharmaceuticals plc | Accardi Mario Alberto | Officer | SELL | $28.83 | 10,000 | $288,289 | 178,801 |
| 2025-12-10 01:00 | 2025-12-05 | RPRX | Royalty Pharma plc | Urist Marshall | Officer | SELL | $39.15 | 41,576 | $1,627,817 | 7,398 |
| 2025-12-10 00:10 | 2025-12-05 | HRMY | Harmony Biosciences Holdings, Inc. | Kapadia Sandip | Officer | OPT+S | $39.54 | 20,000 | $790,896 | 0 |
| 2025-12-10 00:12 | 2025-12-05 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% owner | BUY | $39.61 | 744 | $29,469 | 371,708 |
| 2025-12-10 03:40 | 2025-12-05 | XENE | Xenon Pharmaceuticals Inc. | MORTIMER IAN | Director, Officer | SELL | $45.33 | 25,205 | $1,142,512 | 6,000 |
| 2025-12-10 01:03 | 2025-12-05 | VSTM | Verastem, Inc. | Paterson Dan | Director, Officer | SELL | $10.45 | 6,000 | $62,720 | 414,818 |
| 2025-12-10 02:01 | 2025-12-05 | EBS | Emergent BioSolutions Inc. | Richard Ronald | Director | OPT+S | $11.97 | 21,984 | $263,078 | 98,417 |
| 2025-12-10 02:16 | 2025-12-08 | KALV | KalVista Pharmaceuticals, Inc. | Palleiko Benjamin L | Director, Officer | OPT+S | $16.51 | 7,294 | $120,424 | 424,520 |
| 2025-12-10 00:22 | 2025-12-05 | COLL | COLLEGIUM PHARMACEUTICAL, INC | Balice-Gordon Rita J. | Director | SELL | $47.03 | 3,650 | $171,673 | 52,629 |
| 2025-12-10 03:13 | 2025-12-05 | ALMS | Alumis Inc. | AKKARAJU SRINIVAS | Director | BUY | $9.84 | 186,377 | $1,833,763 | 1,265,253 |
| 2025-12-10 00:36 | 2025-12-05 | MRVI | MARAVAI LIFESCIENCES HOLDINGS, INC. | LUCIER GREGORY T | Director | BUY | $3.69 | 100,000 | $368,540 | 155,123 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.